CG Oncology, Inc. is a clinical-stage biopharmaceutical company dedicated to the research and development of targeted immunotherapies for urologic cancers. The company's primary focus is on addressing significant unmet medical needs in bladder cancer through its proprietary oncolytic immunotherapy platform. Its lead asset, cretostimogene grenadenorepvec, is an intravesically delivered, genetically engineered oncolytic virus designed to selectively replicate in and destroy tumor cells while stimulating an anti-tumor immune response. The therapy is currently advancing through late-stage clinical development, including the pivotal Phase 3 BOND-003 trial for patients with high-risk non-muscle invasive bladder cancer (NMIBC) who are unresponsive to standard Bacillus Calmette-Guérin (BCG) therapy.
As a pre-commercial entity, CG Oncology does not yet generate commercial product revenue and operates at a net loss. The company funds its extensive research, development, and clinical trial activities through equity financing, including a successful initial public offering in January 2024 and subsequent at-the-market offerings. The company is actively preparing for its first Biologics License Application (BLA) submission to the FDA. Geographically, the company is headquartered in Irvine, California, and conducts clinical trials across multiple sites. Its competitive position hinges on the potential of cretostimogene to serve as a backbone bladder-sparing therapy, offering a highly anticipated alternative to radical cystectomy for patients with limited treatment options.
